Tuoxin Pharmaceutical Group Co.,Ltd.

301089

CNE100004YC3

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
34.85 ^CNY	+0.11%		-4.28%	-35.47%

05-14	Tuoxin Pharmaceutical Group Co.,Ltd. Approves 2023 Profit Distribution Plan	CI
05-14	Tuoxin Pharmaceutical Group Co.,Ltd. Elects Lin Xiansheng and Yang Shaohua as Non-Independent Directors	CI

Xinxiang Tuoxin Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 601.965 million.

October 22, 2021 at 05:00 am

Xinxiang Tuoxin Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 601.965 million.

Security Name: A Shares
Security Type: Common Stock
Securities Offered: 31,500,000
PriceRange: CNY 19.11

Latest news about Tuoxin Pharmaceutical Group Co.,Ltd.

Tuoxin Pharmaceutical Group Co.,Ltd. Approves 2023 Profit Distribution Plan	05-14	CI
Tuoxin Pharmaceutical Group Co.,Ltd. Elects Lin Xiansheng and Yang Shaohua as Non-Independent Directors	05-14	CI
Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-22	CI
Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-22	CI
Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23	CI
Tuoxin Pharmaceutical Group Co.,Ltd.(XSEC:301089) added to S&P Global BMI Index	18/09/23	CI
Tuoxin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Approves the Cash Dividend for the Year 2022, Payment Date: 06 June 2023	31/05/23	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. has Changed its Name to Tuoxin Pharmaceutical Group Co., Ltd	26/05/23	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Approves the Cash Dividend for the Year 2022	18/05/23	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for the Year of 2022	26/04/23	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23	CI
Xinxiang Tuoxin Pharma to Form New Chemical Products Subsidiary	17/03/23	MT
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	20/10/22	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22/08/22	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 25, 2022	18/05/22	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2021	17/05/22	CI
Tuoxin Pharmaceutical to Free Up 1.5 Million Shares For Trading; Shares Tank 5%	26/04/22	MT
Xinxiang Tuoxin Pharma’s 2021 Profit Plunges 42% as Sales Slip 5%	25/04/22	MT
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Proposes Final Dividend for 2021	22/04/22	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	21/04/22	CI
Xinxiang Tuoxin Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	21/04/22	CI
Xinxiang Changtong Industrial Co., Ltd. announced that it has received CNY 17 million in funding from Xinxiang Tuoxin Pharmaceutical Co.,Ltd.	21/11/21	CI
Xinxiang Changtong Industrial Co., Ltd. announced that it expects to receive CNY 17 million in funding from Xinxiang Tuoxin Pharmaceutical Co.,Ltd.	09/11/21	CI

Chart Tuoxin Pharmaceutical Group Co.,Ltd.

Duration

Period

Chart Tuoxin Pharmaceutical Group Co.,Ltd.

More charts

Company Profile

Tuoxin Pharmaceutical Group Co Ltd, formerly Xinxiang Tuoxin Pharmaceutical Co Ltd, is a Chinese company mainly engaged in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates. The Company's main products include pyrimidine series, purine series, nucleotide series, nucleoside series and other series of nucleoside (acid) products, including citicoline sodium, ribavirin, inosine, acyclovir, azvudine, cytosine, 5-fluorocytosine, cytidine, uridine and other raw materials and pharmaceutical intermediates. Its products are mainly used in the fields of virus, anti-tumor and nervous system drugs. The Company mainly distributes its products in domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
TUOXIN PHARMACEUTICAL GROUP CO.,LTD.	-35.47%	609M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B